CN109645295A - A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health - Google Patents
A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health Download PDFInfo
- Publication number
- CN109645295A CN109645295A CN201910045542.3A CN201910045542A CN109645295A CN 109645295 A CN109645295 A CN 109645295A CN 201910045542 A CN201910045542 A CN 201910045542A CN 109645295 A CN109645295 A CN 109645295A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- haematococcus pluvialis
- powder
- solid beverage
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 70
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 70
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 70
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 70
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 70
- 241000168517 Haematococcus lacustris Species 0.000 title claims abstract description 55
- 235000013361 beverage Nutrition 0.000 title claims abstract description 38
- 239000007787 solid Substances 0.000 title claims abstract description 33
- 230000036541 health Effects 0.000 title claims abstract description 30
- 210000000748 cardiovascular system Anatomy 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 65
- 241000209140 Triticum Species 0.000 claims abstract description 30
- 235000021307 Triticum Nutrition 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 24
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 24
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims abstract description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 235000019441 ethanol Nutrition 0.000 claims description 31
- 239000003513 alkali Substances 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 24
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 19
- 108010059892 Cellulase Proteins 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 229940106157 cellulase Drugs 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 240000007087 Apium graveolens Species 0.000 claims description 16
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 16
- 235000010591 Appio Nutrition 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 241000168525 Haematococcus Species 0.000 claims description 8
- 244000273928 Zingiber officinale Species 0.000 claims description 8
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 235000008397 ginger Nutrition 0.000 claims description 8
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- 229920002752 Konjac Polymers 0.000 claims description 6
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 6
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 6
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 6
- 235000021014 blueberries Nutrition 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000004042 decolorization Methods 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 229940029982 garlic powder Drugs 0.000 claims description 5
- 235000013311 vegetables Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 244000291564 Allium cepa Species 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910001882 dioxygen Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 235000013305 food Nutrition 0.000 abstract description 19
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 abstract description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 3
- 208000006011 Stroke Diseases 0.000 abstract description 3
- 230000008822 capillary blood flow Effects 0.000 abstract description 3
- 231100000481 chemical toxicant Toxicity 0.000 abstract description 3
- 210000003038 endothelium Anatomy 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000234282 Allium Species 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006318 protein oxidation Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000020795 whole food diet Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health, the raw materials including following mass percentage content: astaxanthin 5~15%, mannan-oligosaccharides 30~35%, wheat oligopeptide 20~30%, Herba Apii graveolentis extract 20~30% and vitamin C 0.5~1%.The present invention is on the basis of traditional astaxanthin food, the resource food for arranging in pairs or groups new, a kind of new beverage food obtained after scientific compatibility, it takes more convenient, this product need to be only melted in wet suit use, it can take for a long time, hypertension can be not only reduced after taking, the probability of apoplexy and heart attack, enhance capillary blood flow and blood antioxidant quality, improve blood vessel endothelium health, it can also assist reducing blood lipid, blood glucose, and ingredient is natural, it has no toxic and side effect to human body, side effect will not be generated as drug, and lower chemical toxicant is remained in vivo.
Description
Technical field
The invention belongs to technical field of food production, and in particular to a kind of haematococcus pluvialis for maintaining cardiovascular system health
Astaxanthin solid beverage.
Background technique
Cardiovascular and cerebrovascular disease can be divided into cardiovascular disease and cranial vascular disease.Cardiovascular disease based on coronary heart disease, be by
Atherosis occurs in the coronary artery to cardiac muscle supply blood, so that arteries is narrowed or is occluded, deficiency myocardial blood supply causes
Can clinically be divided into latent coronary heart disease, angina pectoris, myocardial infarction, myocardial fibrosis and sudden cardiac death.Cerebrovascular disease be
On the basis of cerebral arteriovenous malformation, rupture of blood vessel in brain bleeding or thrombosis cause with cerebral haemorrhage or ischemia injury to be main
One group of disease of clinical manifestation is commonly called as headstroke, is the principal disease for causing human death at present He disabling.Battalion in blood
Feeding substance and oxygen are cell, tissue and organ are required.The direct performance of cardiovascular and cerebrovascular disease is blood flow, especially dynamic
Arteries and veins blood flow occurs abnormal.The nitric oxide production adjusting that vascular endothelial cell generates is received in the diastole of blood vessel, and eNOS enzyme activity is
Characterize the important indicator of vasodilatory capabilities.It improves blood flow and is especially arterial vascular blood flow, can significantly improve because lacking
Cardiovascular and cerebrovascular disease caused by blood.
Haematococcus pluvialis is the highest biology of natural astaxanthin content, and on other occasions, haematococcus pluvialis can accumulate
The tired astaxanthin for accounting for its 1% or more dry weight, and astaxanthin structure required for the mechanism of institute's astaxanthin-containing and cultivation object first is that,
It is acknowledged as the best biological source of natural astaxanthin.A kind of fat soluble carotenoids, have inoxidizability, it is antitumor and
The many important physiology and biological function such as strengthen immunity, inoxidizability are 500~1000 times of vitamin E, for recklessly
10 times of radish element, are the powerful antioxidants generally acknowledged in hydrobiontic alga, can inhibit senile plaque in human body by anti-oxidant
It is formed, fatigue tool is inspected to video display terminal operator and is improved significantly, additionally aids what elimination was generated by the time difference
Physical discomfort, effect are also more obvious than common epiphysin.So there is astaxanthin important nutritive value and dietotherapy to make
With being unanimously generally acknowledged on food products market both at home and abroad at present to have antioxidant activity, antitumor and strengthen immunity etc. many heavy
The raw material of the wholefood of the physiology and biological function wanted.
Currently, the product of adjuvant therapy of cardiovascular disease is usually drug and health care product, the raw material that drug uses is chemistry
Synthesis or microbial fermentation product, health care product are mostly Chinese medicine using raw material, although there is auxiliary to control for these drugs and health care product
The effect of cardiovascular disease is treated, but these drugs or health care product all have some toxic side effects.With astaxanthin exploitation and
It utilizes, also occurs the food of a series of capsule based on astaxanthin, tablet in the market, but these contain astaxanthin
The generally existing price of food is high, is not easy to eat, and treats the unconspicuous feature of illness effect.Therefore, a kind of formula is developed
It is unique, convenient, can be eaten for a long time, have no toxic side effect, can significantly increase antioxidant effect and treatment illness effect it is apparent
The Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health is desirability.
Summary of the invention
In order to solve the problems, such as background technique, it is unique, edible square that the purpose of the present invention is to provide a kind of formulas
Just, it can be eaten for a long time, have no toxic side effect, antioxidant effect can be significantly increased and treatment illness effect significantly remains cardiovascular
The Astaxanthin In Haematococcus Pluvialis solid beverage of system health.
The Astaxanthin In Haematococcus Pluvialis solid beverage of the present invention for maintaining cardiovascular system health, including following quality
The raw material of degree: astaxanthin 5~15%, mannan-oligosaccharides 30~35%, wheat oligopeptide 20~30%, Herba Apii graveolentis extract
20~30% and vitamin C 0.5~1%.
The Astaxanthin In Haematococcus Pluvialis solid beverage is first by astaxanthin 5~15%, mannan-oligosaccharides 30~35%, wheat
Oligopeptide 20~30%, Herba Apii graveolentis extract 20~30% and vitamin C 0.5~1% stir 20~30min in blender, then will
Mixture after stirring and evenly mixing is sent into boiling type granulation tower and is granulated, when granulation temperature control at 30~45 DEG C, the time is 20~
30min, being granulated after obtained particle cools down later can be obtained finished product.
Further, the Astaxanthin In Haematococcus Pluvialis solid beverage also include mass percentage content be 1~3% it is auxiliary
Expect the flavoring agent with 0.2~0.5%.
Preferably, the auxiliary material includes the component of following mass parts: 15~20 parts of Kelp Powder, 40~50 parts of ginger powder, garlic
10~20 parts and 5~10 parts of onion powder of powder.
Preferably, the flavoring agent be fructus lycii dry powder, blueberry dry powder, apple dry powder and one of which in lemon dry powder or
Two or more mixtures.
Wherein, the wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation.
Preferably, the mannan-oligosaccharides are konjaku Oligomeric manna sugar powder.
Preferably, the preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, later after grinding
Haematococcus pluvialis powder in cellulase and pectase be added carry out broken wall, the amount that cellulase is added is haematococcus pluvialis matter
The 1~2% of amount, the amount that cellulase is added is the 0.2~0.8% of haematococcus pluvialis quality, and broken wall temperature is 0~4 DEG C, broken wall 1
After~2h, then haematococcus pluvialis powder is dipped in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% and carries out ultrasound
Wave extracts, and the temperature of ultrasonic wave extraction is 40~50 DEG C, and the power of ultrasonic wave is 300~400W, after 10~20min of ultrasonic extraction
Extract is filtered, the filtrate being obtained by filtration carries out vacuum freeze drying again, and the vacuum degree of freeze-drying is 0.5 × 10-1
~2 × 10-1Mbar, dry temperature are -30~-50 DEG C, and astaxanthin can be obtained after dry 5~10h.
Preferably, the preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes
Obtain celery powder, then by the ethanol water that celery powder and mass fraction are 75% by solid-liquid ratio to be that 1:5~8 mix laggard
Row alcohol extracting, 40~60min of alcohol extracting obtain alcohol extract, later again by alcohol extract respectively membrane aperture be 100~120mm, feed liquid temperature
Ultrafiltration is carried out under the conditions of degree is 30~40 DEG C, ultrafiltration pressure is 0.1~0.2MPa and obtains filtrate, is finally 8 in pH value by filtrate
~10,40~60min of alkali carries obtains alkali extract under conditions of temperature is 45~55 DEG C, then mass fraction is added in alkali extract and is
30% hydrogen peroxide carries out decolorization and obtains destainer, and the ratio of hydrogen peroxide and alkali extract is 1:2~3, later again by destainer
It is filtered, the obtained filtrate of filtering is spray-dried again, can be prepared by Herba Apii graveolentis extract.
Ingredient and the mechanism of action are as follows the effect of each raw material in the present invention:
Astaxanthin is the highest level product of a kind of fat soluble carotenoids and carotenogenesis, is in rediance,
Chemical structure is similar to beta carotene.Astaxanthin is one of strongest natural in the world, can effectively clear cell
Interior oxygen radical enhances cytothesis ability, maintains organism balance and reduces the accumulation of senile cell, protection is thin from inside to outside
Born of the same parents and DNA health promote hair growth to protect skin health, and anti-aging alleviates sports fatigue, invigorates.Both at home and abroad
Numerous studies confirm that astaxanthin has stronger antioxidant activity, are improving immunity, pre- preventing tumor, cardiovascular disease, glycosuria
The occurrence and development of the chronic diseases such as disease, delay senescence etc. have positive facilitation.
Mannan-oligosaccharides have low-heat, stabilization.The good physicochemical property such as safe and non-toxic, also there is good stomach to adjust
Function has both good bifidobacterium growth activity, has effects that protect enteron aisle, improves immunity.
Wheat oligopeptide is the protein extracted from wholefood gluten powder, using orientation digestion and specific small
The micromolecule polypeptide substance that peptide isolation technics obtains.The wheat oligopeptide belongs to new resource food, is rich in glutamic acid and paddy
The nutritional ingredients such as glutamine, can be improved immunity, can be antifatigue；Especially there is reducing blood lipid, blood pressure lowering is hypoglycemic, antithrombotic,
Play the role of that cholesterol is inhibited to rise；Improve diabetic symptom；It can also be used as particular nutrient when intestinal dysfunction simultaneously.
Herba Apii graveolentis extract contains a large amount of cellulose, first is that angiotensins level can be significantly reduced, reduces systolic pressure
And diastolic pressure, have effects that reduce blood pressure, second is that can promote enteron aisle that residue is discharged, reduces the absorption of cholesterol.
The beneficial effect comprise that: first is that raw material of the present invention be health ministry approval be both
Food is the article of drug again, and nutritive value is abundant, rich in abundant antioxidant content, belongs to natural food；Second is that of the invention
It is astaxanthin, mannan-oligosaccharides %, wheat oligopeptide, Herba Apii graveolentis extract and vitamin C through science with the food being made into, both protected
Held the supply of raw material nutrition, but allow it is mutual promoted the effect of preventing and curing diseases, can effectively prevent low close in blood
The risk that degree albumen is oxidized；Third is that product of the present invention target user's range is wide, ordinary populace and hyperglycemia, hypertension and heart and brain
Vascular patients etc. are edible, and Herba Apii graveolentis extract, which is added, can lower cholesterol, and wheat oligopeptide and mannan-oligosaccharides can be
Edible crowd provides lecithin, balances the secretion of insulin, can adjust blood glucose and blood pressure；Fourth is that the present invention also uses celery
As major ingredient, one side celery belongs to the material of integration of drinking and medicinal herbs, without any side effects, another party more effective to blood pressure lowering
Face celery is easy to get, is cheap, is well-known big.
To sum up, the present invention is on the basis of traditional astaxanthin food, the resource food for arranging in pairs or groups new, obtains after scientific compatibility
A kind of new beverage food, take it is more convenient, only this product need to be melted in wet suit use, can take for a long time, take
The free radical and intracellular free radical between human body cell can be not only eliminated after, protect cells from peroxidization
Injury, enables cell normally effectively to carry out metabolism, can prevent plasma low density protein oxidation, while can also show
It writes increasing high density lipoprotein and reduces low-density lipoprotein, reduce the formation of plaque deposition, restore blood vessel elasticity, improve blood
Flowing enhances capillary blood flow and blood antioxidant matter to reduce hypertension, apoplexy and the probability of heart attack
Amount improves blood vessel endothelium health, can also assist reducing blood lipid, blood glucose, and ingredient is natural, have no toxic and side effect to human body, will not
As drug generation side effect, and lower chemical toxicant is remained in vivo.It is a kind of food specifically for cardiovascular and cerebrovascular disease research and development,
Be formulated it is unique, convenient, can be eaten for a long time, have no toxic side effect, can significantly increase antioxidant effect and treatment illness imitate
Fruit clear advantage, use easy to spread.
Specific embodiment
Below with reference to embodiment, the present invention is further illustrated, but the present invention is limited in any way,
Based on present invention teach that it is made it is any transform or replace, all belong to the scope of protection of the present invention.
Embodiment 1:
The Astaxanthin In Haematococcus Pluvialis solid beverage of cardiovascular system health, including following quality are maintained described in the present embodiment 1
The raw material of degree: astaxanthin 5%, mannan-oligosaccharides 35%, wheat oligopeptide 30%, Herba Apii graveolentis extract 29.5% and vitamin
C 0.5%。
The Astaxanthin In Haematococcus Pluvialis solid beverage is astaxanthin 5%, mannan-oligosaccharides 35%, wheat oligopeptide 30%, celery
Dish extract 29.5% and vitamin C 0.5% stir 20min in blender, then the mixture after stirring and evenly mixing is sent into boiling
Be granulated in formula granulation tower, when granulation temperature control at 30 DEG C, time 20min, will be granulated later obtained particle it is cooling after i.e.
Finished product can be obtained.
Wherein: wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation, can be passed through
It is directly commercially available in the market.
The mannan-oligosaccharides are konjaku Oligomeric manna sugar powder, can be directly commercially available by the market.
The preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, rain later after grinding is raw
Cellulase is added in haematococcus powder and pectase carries out broken wall, the amount that cellulase is added is haematococcus pluvialis quality
1%, the amount that cellulase is added is the 0.2% of haematococcus pluvialis quality, and broken wall temperature is 0 DEG C, after broken wall 1h, then by the raw red ball of rain
Algae powder is dipped in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% and carries out ultrasonic wave extraction, ultrasonic wave extraction
Temperature is 40 DEG C, and the power of ultrasonic wave is 300W, is filtered extract after ultrasonic extraction 10min, the filtrate being obtained by filtration
Vacuum freeze drying is carried out again, and the vacuum degree of freeze-drying is 0.5 × 10-1Mbar, dry temperature are -30 DEG C, after dry 5h
Astaxanthin can be obtained.
The preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes and obtain celery
Vegetable powder end, then the ethanol water for being 75% by celery powder and mass fraction by solid-liquid ratio is that alcohol extracting, alcohol are carried out after 1:5 is mixed
It mentions 40min and obtains alcohol extract, later again by alcohol extract respectively membrane aperture is 100mm, feed liquid temperature is 30 DEG C, ultrafiltration pressure is
Under the conditions of 0.1MPa carry out ultrafiltration obtain filtrate, finally by filtrate under conditions of pH value is 8, temperature is 45 DEG C alkali carries 40min
Alkali extract is obtained, then the hydrogen peroxide progress decolorization that mass fraction is 30% is added in alkali extract and obtains destainer, hydrogen peroxide
Ratio with alkali extract is 1:2, is later again filtered destainer, the obtained filtrate of filtering is spray-dried again, i.e.,
Herba Apii graveolentis extract can be made.
Embodiment 2
The Astaxanthin In Haematococcus Pluvialis solid beverage of cardiovascular system health, including following quality are maintained described in the present embodiment 2
The raw material of degree: astaxanthin 10%, mannan-oligosaccharides 33%, wheat oligopeptide 30%, Herba Apii graveolentis extract 25%, vitamin C
0.8%, 1% auxiliary material and 0.2% flavoring agent.
The Astaxanthin In Haematococcus Pluvialis solid beverage is first by astaxanthin 10%, mannan-oligosaccharides 33%, wheat oligopeptide
30%, Herba Apii graveolentis extract 25%, 0.8%, 1% auxiliary material of vitamin C and 0.2% flavoring agent stir 20~30min in blender,
Mixture after stirring and evenly mixing again is sent into boiling type granulation tower and is granulated, when granulation temperature control be in 30~45 DEG C, time
20~30min, being granulated after obtained particle cools down later can be obtained finished product
Wherein:
The auxiliary material includes the component of following mass parts: 20 parts of Kelp Powder, 50 parts of ginger powder, 20 parts of garlic powder and 10 parts of onion powder,
Traditional kelp mainly directly uses dry kelp, then cutting soaking and water washing is ground using colloid mill to produce dietetic food,
The present embodiment is then using making water sublimed after softening, freeze-drying, then grinds and Kelp Powder is made is used, and not only removes fishy smell, changes
Good mouthfeel and the laminarin that kelp is rich in is remained, there is better therapeutic effect, ginger powder is taken ginger slice low temperature
Vacuum pressed drying and dehydrating is ground into powder again after freezing and the method screened obtains；Garlic powder is powder after being dehydrated garlic
It is broken into powder, then saves and obtains under low temperature drying environment；Onion is frequently with juicing heating or General low temperature freeze-drying, vacuum drying
Mode, these processing modes can make sulfide decompose or retain it is less, and the present embodiment take it is broken, micro- after cutting, be concentrated very
The dry mode of sky, effective component reach maximum reservation.
The flavoring agent be fructus lycii dry powder, blueberry dry powder, apple dry powder and one of which in lemon dry powder or two kinds with
On mixture, fructus lycii dry powder, blueberry dry powder, apple dry powder and lemon dry powder have fruity, product can be increased after addition
Nutritional ingredient improves the mouthfeel of beverage, adjusts the flavor of beverage, the people that are more suitable reference.
Wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation, can be by the market
Directly it is commercially available.
The mannan-oligosaccharides are konjaku Oligomeric manna sugar powder, can be directly commercially available by the market.
The preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, rain later after grinding is raw
Cellulase is added in haematococcus powder and pectase carries out broken wall, the amount that cellulase is added is haematococcus pluvialis quality
1.5%, the amount that cellulase is added is the 0.6% of haematococcus pluvialis quality, and broken wall temperature is 2 DEG C, after broken wall 1.5h, then rain is raw
Haematococcus powder is dipped in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% and carries out ultrasonic wave extraction, and ultrasonic wave mentions
The temperature taken is 45 DEG C, and the power of ultrasonic wave is 350W, is filtered extract after ultrasonic extraction 18min, is obtained by filtration
Filtrate carries out vacuum freeze drying again, and the vacuum degree of freeze-drying is 0.5 × 10-1Mbar, dry temperature are -40 DEG C, drying 5
Astaxanthin can be obtained after~10h.
The preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes and obtain celery
Vegetable powder end, then the ethanol water for being 75% by celery powder and mass fraction by solid-liquid ratio is that alcohol extracting, alcohol are carried out after 1:7 is mixed
It mentions 50min and obtains alcohol extract, later again by alcohol extract respectively membrane aperture is 110mm, feed liquid temperature is 35 DEG C, ultrafiltration pressure is
Under the conditions of 0.15MPa carry out ultrafiltration obtain filtrate, finally by filtrate under conditions of pH value is 9, temperature is 50 DEG C alkali carries 40~
60min obtains alkali extract, then the hydrogen peroxide progress decolorization that mass fraction is 30% is added in alkali extract and obtains destainer,
The ratio of hydrogen peroxide and alkali extract is 1:2.5, is later again filtered destainer, the obtained filtrate of filtering is sprayed again
It is dry, it can be prepared by Herba Apii graveolentis extract.
Embodiment 3
The Astaxanthin In Haematococcus Pluvialis solid beverage of cardiovascular system health, including following quality are maintained described in the present embodiment 3
The raw material of degree: astaxanthin 15%, mannan-oligosaccharides 35%, wheat oligopeptide 25.5%, Herba Apii graveolentis extract 20% and Wei Sheng
Plain 1%, 3% auxiliary material of C and 0.5% flavoring agent.
The Astaxanthin In Haematococcus Pluvialis solid beverage is first by astaxanthin 15%, mannan-oligosaccharides 35%, wheat oligopeptide
25.5%, Herba Apii graveolentis extract 20% and 1%, 3% auxiliary material of vitamin C and 0.5% flavoring agent stir 28min in blender, then
Mixture after stirring and evenly mixing is sent into boiling type granulation tower and is granulated, when granulation temperature control at 38 DEG C, time 30min,
To be granulated after obtained particle cools down later can be obtained finished product.
Wherein the accessory package includes the component of following mass parts: 15 parts of Kelp Powder, 40 parts of ginger powder, 10 parts of garlic powder and onion
5 parts of powder；Traditional kelp mainly directly uses dry kelp, then cutting soaking and water washing grinds to produce food using colloid mill
Product, the present embodiment is then using making water sublimed after softening, freeze-drying, then grinds and Kelp Powder is made is used, and not only removes fishy smell,
Improvement mouthfeel and remain the laminarin that kelp is rich in, there is better therapeutic effect, ginger powder be take ginger slice is low
Vacuum pressed drying and dehydrating is ground into powder again after temperature freezing and the method screened obtains；Garlic powder is after being dehydrated garlic
It is ground into powder, then saves and obtains under low temperature drying environment；Onion does frequently with juicing heating or General low temperature freeze-drying, vacuum
Dry mode, these processing modes can make sulfide decompose or retain it is less, and the present embodiment take it is broken, micro- after cutting, being concentrated
Vacuum drying mode, effective component reach maximum reservation.
The flavoring agent be fructus lycii dry powder, blueberry dry powder, apple dry powder and one of which in lemon dry powder or two kinds with
On mixture, fructus lycii dry powder, blueberry dry powder, apple dry powder and lemon dry powder have fruity, product can be increased after addition
Nutritional ingredient improves the mouthfeel of beverage, adjusts the flavor of beverage, the people that are more suitable reference.
Wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation, can be by the market
Directly it is commercially available.
The mannan-oligosaccharides are konjaku Oligomeric manna sugar powder, can be directly commercially available by the market.
The preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, rain later after grinding is raw
Cellulase is added in haematococcus powder and pectase carries out broken wall, the amount that cellulase is added is the 1 of haematococcus pluvialis quality
~2%, the amount that cellulase is added is the 0.6% of haematococcus pluvialis quality, and broken wall temperature is 3 DEG C, after broken wall 1.5h, then rain is raw
Haematococcus powder is dipped in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% and carries out ultrasonic wave extraction, and ultrasonic wave mentions
The temperature taken is 50 DEG C, and the power of ultrasonic wave is 380W, is filtered extract after ultrasonic extraction 18min, is obtained by filtration
Filtrate carries out vacuum freeze drying again, and the vacuum degree of freeze-drying is 0.5 × 10-1Mbar, dry temperature is -45 DEG C, dry
Astaxanthin can be obtained after 8h.
The preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes and obtain celery
Vegetable powder end, then the ethanol water for being 75% by celery powder and mass fraction by solid-liquid ratio is that alcohol extracting, alcohol are carried out after 1:7 is mixed
It mentions 60min and obtains alcohol extract, later again by alcohol extract respectively membrane aperture is 110mm, feed liquid temperature is 38 DEG C, ultrafiltration pressure is
Under the conditions of 0.1 MPa carry out ultrafiltration obtain filtrate, finally by filtrate under conditions of pH value is 9, temperature is 50 DEG C alkali carries 55min
Alkali extract is obtained, then the hydrogen peroxide progress decolorization that mass fraction is 30% is added in alkali extract and obtains destainer, hydrogen peroxide
Ratio with alkali extract is 1:2.5, is later again filtered destainer, and the obtained filtrate of filtering is spray-dried again,
It can be prepared by Herba Apii graveolentis extract.
Embodiment 4
The Astaxanthin In Haematococcus Pluvialis solid beverage of cardiovascular system health, including following quality hundred are maintained described in the present embodiment 4
Divide the raw material than content: astaxanthin 12%, mannan-oligosaccharides 34%, wheat oligopeptide 28%, Herba Apii graveolentis extract 25% and vitamin C
1%。
The Astaxanthin In Haematococcus Pluvialis solid beverage is first by astaxanthin 12%, mannan-oligosaccharides 34%, wheat oligopeptide
28%, Herba Apii graveolentis extract 25% and vitamin C 1% stir 30min in blender, then the mixture after stirring and evenly mixing is sent into boiling
Rise in formula granulation tower and be granulated, when granulation temperature control at 45 DEG C, time 30min, will be granulated later obtained particle it is cooling after
Finished product can be obtained.
Wherein: the wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation.
The mannan-oligosaccharides are konjaku Oligomeric manna sugar powder.
The preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, rain later after grinding is raw
Cellulase is added in haematococcus powder and pectase carries out broken wall, the amount that cellulase is added is haematococcus pluvialis quality
2%, the amount that cellulase is added is the 0.8% of haematococcus pluvialis quality, and broken wall temperature is 4 DEG C, after broken wall 2h, then by the raw red ball of rain
Algae powder is dipped in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% and carries out ultrasonic wave extraction, ultrasonic wave extraction
Temperature is 50 DEG C, and the power of ultrasonic wave is 400W, is filtered extract after ultrasonic extraction 20min, the filtrate being obtained by filtration
Vacuum freeze drying is carried out again, and the vacuum degree of freeze-drying is 2 × 10-1Mbar, dry temperature are -50 DEG C, after dry 10h i.e.
Astaxanthin can be obtained.
The preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes and obtain celery
Vegetable powder end, then the ethanol water for being 75% by celery powder and mass fraction by solid-liquid ratio is that alcohol extracting, alcohol are carried out after 1:8 is mixed
It mentions 60min and obtains alcohol extract, later again by alcohol extract respectively membrane aperture is 120mm, feed liquid temperature is 40 DEG C, ultrafiltration pressure is
Under the conditions of 0.2MPa carry out ultrafiltration obtain filtrate, finally by filtrate under conditions of pH value is 10, temperature is 55 DEG C alkali carries 60min
Alkali extract is obtained, then the hydrogen peroxide progress decolorization that mass fraction is 30% is added in alkali extract and obtains destainer, hydrogen peroxide
Ratio with alkali extract is 1:3, is later again filtered destainer, the obtained filtrate of filtering is spray-dried again, i.e.,
Herba Apii graveolentis extract can be made.
Main astaxanthin-containing in the present embodiment 1~4, with mannan-oligosaccharides, wheat oligopeptide %, Herba Apii graveolentis extract and vitamin
Complementation can not only eliminate free radical and intracellular free radical between human body cell, protect cells from peroxidization
Injury, so that cell is normally effectively carried out metabolism, plasma low density protein oxidation can be prevented, while can also
Significant increasing high density lipoprotein and reduction low-density lipoprotein, reduce the formation of plaque deposition, restore blood vessel elasticity, improve blood
Liquid stream is dynamic, to reduce hypertension, apoplexy and the probability of heart attack, enhances capillary blood flow and blood antioxidant
Quality improves blood vessel endothelium health, can also assist reducing blood lipid, blood glucose, and ingredient is natural, has no toxic and side effect to human body, no
Side effect can be generated as drug, and remain lower chemical toxicant in vivo, be a kind of food specifically for cardiovascular and cerebrovascular disease research and development
Product.
Astaxanthin In Haematococcus Pluvialis of the invention obtains preferable curative effect, takes the satisfaction of rear curative effect up to 90% or more,
And see safe without toxic side effect, cost is relatively low, can achieve the purpose that treating both manifestation and root cause of disease, is that a kind of safely and effectively maintenance is cardiovascular
The green safe food of system health.According to the formula of above-described embodiment, inventor has carried out 100 people to drink test, 100 people
To there is the patient of different degrees of cardiovascular and cerebrovascular disease, after taking a period of time, inventor pays a return visit above-mentioned crowd,
In have 95 people think the present invention maintain and treat cardiovascular disease in terms of have good curative effect, obtain the consistent good of patient
It comments, satisfaction is up to 95%.Existing special act several test examples therein:
Test example 1: week certain；Male, 44 years old, poor memory, sleep quality was very poor, accidental uncomfortable in chest, palpitation and uneasiness, palpitation and short breath, the heart
Rate is uneven；By suggesting, from August 10th, 10 days 1 May in 2018, adhere to taking the rain prepared by embodiment 1 daily
Raw haematococcus solid beverage 750mL, after 3 months, foregoing conditions all significantly mitigate, and therapeutic index is 96%.
Test example 2: Lee；Male, 55 years old, after pectoralgia, breastbone or precordialgia, gas was tight, syncope, weak, belch, skin
There is color spot；By suggesting, from July 10,10 days to 2018 May in 2018, adheres to taking daily and be made by embodiment 2
Standby haematococcus pluvialis solid beverage 750mL, after two months, after pectoralgia, breastbone or precordialgia, gas is tight, syncope, it is weak,
The illnesss such as belch significantly mitigate, and color spot disappearance 90%, therapeutic index is 85%.
Test example 3: Mr. Wang；Female, 30 years old, scalp was often numb, blood supply in brain is insufficient；Through suggestion, from May, 2018 to
October by August 10th, 2018, adheres to taking the haematococcus pluvialis solid beverage 750mL prepared by embodiment 3 daily；3 months
Afterwards, foregoing conditions all significantly mitigate, and cardiovascular and cerebrovascular disease substantially eliminates, and therapeutic index is 95.2%.
Test example 4: Chen；Female, 40 years old, poor sleeping quality was dizzy, decrease of memory, and eyes are often baffled fuzzy, and gallbladder is solid
Alcohol and blood lipid are exceeded, by suggesting, from May, 2018 to October by August 10th, 2018, adhere to taking by embodiment 4 daily
The haematococcus pluvialis solid beverage 750mL of preparation；After 3 months, blood lipid and cholesterol value are checked close to normal value, sleep quality obtains
To improvement, therapeutic index is 96%.
Claims (9)
1. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health, it is characterised in that: including following matter
Measure the raw material of degree: astaxanthin 5~15%, mannan-oligosaccharides 30~35%, wheat oligopeptide 20~30%, celery extract
Object 20~30% and vitamin C 0.5~1%.
2. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the Astaxanthin In Haematococcus Pluvialis solid beverage also include mass percentage content be 1~3% auxiliary material and 0.2~
0.5% flavoring agent.
3. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 2,
Be characterized in that: the auxiliary material includes the component of following mass parts: 15~20 parts of Kelp Powder, 40~50 parts of ginger powder, garlic powder 10~
20 parts and 5~10 parts of onion powder.
4. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 2,
Be characterized in that: the flavoring agent be fructus lycii dry powder, blueberry dry powder, apple dry powder and one of which in lemon dry powder or two kinds with
On mixture.
5. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the wheat oligopeptide is a variety of short-peptide mixtures that wheat bone protein powder is obtained by enzyme degradation.
6. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the mannan-oligosaccharides are konjaku Oligomeric manna sugar powder.
7. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the preparation method of the astaxanthin is: haematococcus pluvialis first being carried out cryogrinding, rain later after grinding is raw
Cellulase is added in haematococcus powder and pectase carries out broken wall, the amount that cellulase is added is the 1 of haematococcus pluvialis quality
~2%, the amount that cellulase is added is the 0.2~0.8% of haematococcus pluvialis quality, and broken wall temperature is 0~4 DEG C, 1~2h of broken wall
Afterwards, then haematococcus pluvialis powder progress ultrasonic wave in the mixed liquor of ethyl alcohol and ethyl acetate that mass fraction is 75% is dipped in mention
It takes, the temperature of ultrasonic wave extraction is 40~50 DEG C, and the power of ultrasonic wave is 300~400W, will be mentioned after 10~20min of ultrasonic extraction
Object is taken to be filtered, the filtrate being obtained by filtration carries out vacuum freeze drying again, and the vacuum degree of freeze-drying is 0.5 × 10-1~2 ×
10-1Mbar, dry temperature are -30~-50 DEG C, and astaxanthin can be obtained after dry 5~10h.
8. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the preparation method of the Herba Apii graveolentis extract is: crushing after fresh celery is dried, crosses 80 meshes and obtain celery
Vegetable powder end, then the ethanol water for being 75% by celery powder and mass fraction by solid-liquid ratio is that alcohol extracting is carried out after 1:5~8 mix,
40~60min of alcohol extracting obtains alcohol extract, later again by alcohol extract respectively membrane aperture be 100~120mm, feed liquid temperature be 30~
40 DEG C, ultrafiltration pressure be 0.1~0.2MPa under the conditions of carry out ultrafiltration obtain filtrate, finally by filtrate pH value be 8~10, temperature
40~60min of alkali carries obtains alkali extract under conditions of being 45~55 DEG C, then the dioxygen that mass fraction is 30% is added in alkali extract
Water carries out decolorization and obtains destainer, and the ratio of hydrogen peroxide and alkali extract is 1:2~3, is later again filtered destainer,
The obtained filtrate of filtering is spray-dried again, can be prepared by Herba Apii graveolentis extract.
9. a kind of Astaxanthin In Haematococcus Pluvialis solid beverage for maintaining cardiovascular system health according to claim 1,
Be characterized in that: the Astaxanthin In Haematococcus Pluvialis solid beverage is first by astaxanthin 5~15%, mannan-oligosaccharides 30~35%, small
Wheat oligopeptide 20~30%, Herba Apii graveolentis extract 20~30% and vitamin C 0.5~1% stir 20~30min in blender, then
Mixture after stirring and evenly mixing is sent into boiling type granulation tower and is granulated, and temperature control is at 30~45 DEG C when granulation, the time 20
~30min, being granulated after obtained particle cools down later can be obtained finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910045542.3A CN109645295A (en) | 2019-01-17 | 2019-01-17 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910045542.3A CN109645295A (en) | 2019-01-17 | 2019-01-17 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109645295A true CN109645295A (en) | 2019-04-19 |
Family
ID=66119847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910045542.3A Pending CN109645295A (en) | 2019-01-17 | 2019-01-17 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109645295A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338326A (en) * | 2019-07-10 | 2019-10-18 | 中慈保健品科技开发有限公司 | Assist in the treatment of the soybean peptide compounding solid beverage and its preparation method and application of cardiovascular and cerebrovascular |
| CN114588194A (en) * | 2022-03-01 | 2022-06-07 | 沈阳药大生物科技有限公司 | Biological component composition for improving blood viscosity and blood vessel embolism |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375368A (en) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | A kind of prevention of cardiovascular disease repairs nervous system product and preparation method thereof |
| CN107805215A (en) * | 2017-10-18 | 2018-03-16 | 海南三元星生物科技股份有限公司 | A kind of extracting method of astaxanthin |
| CN108065392A (en) * | 2017-12-05 | 2018-05-25 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions |
| CN108272970A (en) * | 2018-03-12 | 2018-07-13 | 厦门劳斯克食品有限公司 | A kind of the plant extract composition and preparation method thereof and solid beverage of auxiliary reducing blood lipid |
| CN108294213A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of inulin solid beverage and preparation method thereof rich in astaxanthin |
-
2019
- 2019-01-17 CN CN201910045542.3A patent/CN109645295A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375368A (en) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | A kind of prevention of cardiovascular disease repairs nervous system product and preparation method thereof |
| CN107805215A (en) * | 2017-10-18 | 2018-03-16 | 海南三元星生物科技股份有限公司 | A kind of extracting method of astaxanthin |
| CN108065392A (en) * | 2017-12-05 | 2018-05-25 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions |
| CN108294213A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of inulin solid beverage and preparation method thereof rich in astaxanthin |
| CN108272970A (en) * | 2018-03-12 | 2018-07-13 | 厦门劳斯克食品有限公司 | A kind of the plant extract composition and preparation method thereof and solid beverage of auxiliary reducing blood lipid |
Non-Patent Citations (2)
| Title |
|---|
| 常映明: "《抗衰老漫谈 点燃生日蛋糕上的第120根蜡烛》", 30 November 2017, 中国医药科技出版社 * |
| 王渊哲: "《健康营养宝典》", 31 January 2005, 外文出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338326A (en) * | 2019-07-10 | 2019-10-18 | 中慈保健品科技开发有限公司 | Assist in the treatment of the soybean peptide compounding solid beverage and its preparation method and application of cardiovascular and cerebrovascular |
| CN114588194A (en) * | 2022-03-01 | 2022-06-07 | 沈阳药大生物科技有限公司 | Biological component composition for improving blood viscosity and blood vessel embolism |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104054769B (en) | A kind of function bread treating angiocardiopathy and preparation method thereof | |
| CN103653147A (en) | Wheat peptide anti-fatigue health drink and preparation method thereof | |
| CN103750328A (en) | Freeze-dried compound berry superfine powder and production method thereof | |
| CN102178313A (en) | Bitter buckwheat nutritious healthy beverage | |
| CN106552105A (en) | A kind of effervescent tablet of enhancing immunity and preparation method thereof | |
| CN106954813A (en) | A kind of whitening health food and preparation method thereof | |
| CN105200105A (en) | Preparation method of oyster protein liver protecting peptide preparation | |
| CN104664511A (en) | Cereal-vegetable-fruit beverage and preparation method thereof | |
| CN109645295A (en) | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health | |
| CN103621631A (en) | Blood sugar reducing yoghourt and processing method | |
| CN104286818B (en) | A kind of salad dressing containing Pollen Maydis and preparation method thereof | |
| CN103263054B (en) | Functional drink capable of reducing blood pressure | |
| CN111467468A (en) | Concentrated nutrient solution containing ginseng, cordyceps militaris, ginger and wolfberry fruit and preparation method thereof | |
| CN105212040A (en) | A kind of composite nutrition powder containing blank corn and preparation method thereof | |
| CN109043249A (en) | A kind of blueberry L-arabinose composite beverage underflow | |
| CN107455699A (en) | A kind of ion Vc composition containing pawpaw and preparation method thereof | |
| CN104673572B (en) | There is anti-senescence wine and the preparation method of maintaining beauty and keeping young | |
| CN108478466B (en) | Ceramide for moisturizing skin and preparation method thereof | |
| KR101227922B1 (en) | Papaya puree and the use of the same | |
| CN107969586A (en) | A kind of lotus fermented beverage and production method | |
| CN109567194A (en) | A kind of selenium-rich highland barley clyster powder, processing method and its application | |
| CN107581609A (en) | A kind of garlic peptide composition | |
| CN103039614A (en) | Blueberry soymilk and preparation method thereof | |
| KR20100131052A (en) | Method for producing pepper paste and pepper paste prepared therefrom | |
| CN108064952A (en) | A kind of preparation method of date-wolfberry fruit functional form blending milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |
|
| RJ01 | Rejection of invention patent application after publication |